FinnGen selects Olink to accelerate leading Population Health Study
UPPSALA, Sweden , June 13, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that FinnGen in Finland will use Olink technology to provide detailed proteomics data to improve understanding of human health.
FinnGen, is a large-scale academic/industrial research collaboration in Finland with the scope to collect and analyze genomic and health data from 500,000 Finnish biobank participants. It is one of the very first personalized medicine projects aiming to provide novel, clinically relevant insights while also constructing a world-class resource that can be applied for future studies.
The FinnGen study has so far identified over 400 new disease-associated loci where the associated gene variant is enriched in the Finnish population. Olink has been chosen by FinnGen to provide comprehensive proteomics profiling of up to 2500 individuals as part of the study. These findings can serve as the basis for further functional studies in combination with high quality proteomics, providing the potential for new insights into disease mechanisms.
“We welcome Olink on board. Olink Proteomics’ cutting-edge technology was selected after consideration of the high data quality, the specificity, and its global recognition from large scale proteomics projects such as the UKBB as the proteomics technology of the future. Olink’s platform will provide detailed and comprehensive proteomics data covering all major biological pathways and processes. These data will be generated from a subset of study participants who carry some of these medically and clinically interesting genetic variants,” said Aarno Palotie, FinnGen Scientific Director from the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. “Olink can help us build a foundation for health innovations and personalized treatments. We hope that our study will stimulate researchers and businesses from around the world to join the journey into personalized healthcare.”
FinnGen brings together Finnish biobanks, University Hospitals and their respective Universities, the Finnish Institute of Health and Welfare (THL), the Finnish Red Cross Blood Service, the Finnish Biobanks - FINBB, leading, international pharmaceutical companies and hundreds of thousands of Finnish citizens.
“We are very pleased to be part of the FinnGen project. The fact that Olink was selected by FinnGen, certainly underscores the trust in Olink and our proprietary Proximity Extension Assay (PEA) technology, which combines high throughput, high-quality protein-level measurements into data that can be trusted to uncover actionable insights which are key to achieving breakthroughs in disease prevention, diagnosis, and treatment,” said Henk Mouthaan, Vice President Salesand Marketing EMEA, Olink Proteomics.
Olink’s platform based on the proprietary PEA technology is developed and optimized to detect and identify with very high specificity 3000 proteins across all major biological pathways for a wide array of sample matrices such as serum and plasma.
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Corporate Communications Manager
Mobile: +46 768 775 275
The FinnGen study, launched in Finland in 2017, is a unique study that combines genome information with digital health care data. The FinnGen study plans to analyze up to 500,000 samples collected by a nation-wide network of Finnish biobanks. The project aims to improve human health through genetic research, and ultimately identify new therapeutic targets and diagnostics for treating numerous diseases. It produces near complete genome variant data from all the 500,000 participants using GWAS genotyping and imputation and will utilize the extensive longitudinal national health register data available on all Finns. FinnGen is an exceptionally broad academic-pharma partnership having considerable public funding support from Business Finland (former Tekes). University of Helsinki is the organization responsible for the study. http://www.finngen.fi/en
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Arcoma vinner viktig upphandling i Finland. (MAR)27.6.2022 13:00:00 CEST | Pressemelding
2022-06-27 PRESSRELEASE Arcoma vinner viktig upphandling i Finland. Arcoma AB har vunnit viktig upphandlingpå upp till 6Arcoma Precision i5-system till ”HUS Medical Imaging Center” i Finland.Tre av systemen kommer att installeras under 2022 och kontraktet har en option på ytterligare tre system för installation under 2023. Det totala ordervärdet är upp till cirka 7,5MSek, beroende på tillval och optioner. Upphandlingen är vunnen av Lifemed Medical Systems som är Arcomas distributör och samarbetspartner i Finland och slutkunden är ”HUS Medical Imaging Center” som är en del av Helsingfors universitetssjukhus. "Vi är mycket glada över denna möjlighet att leverera dessa system till HUS, tillsammans med vår partner Arcoma. Ergonomi, patientsäkerhet och bra bildkvalitet var nyckelfaktorerna i detta anbud och Precision i5 är en perfekt lösning för att möta dessa behov ”, säger Mikko Isoviita, Sales Manager Lifemed Medical Systems. "Det är mycket glädjande att vi genom Lifemed vunnit denna upp
Arcoma wins important procurement in Finland. (MAR)27.6.2022 13:00:00 CEST | Press release
2022-06-27 PRESSRELEASE Arcoma wins important procurement in Finland. Arcoma AB has won important procurement of up to 6 Arcoma Precision i5 systems to “HUS Medical Imaging Center” in Finland. Three of the systems will be installed in 2022 and the contract has an option for three more systems for installation in 2023. The total order value is up to approximately SEK 7.5 million, depending on options. The procurement was won by Lifemed Medical Systems, which is Arcoma's distributor and partner in Finland, and the end customer is the “HUS Medical Imaging Center”, which is part of Helsinki University Hospital. "We are very pleased for this opportunity to supply these systems to HUS, together with our long-term partner Arcoma. Ergonomics, patient safety and good image quality were they key factors in this tender and Precision i5 is a perfect solution to address these needs”, says Mikko Isoviita, Sales Manager Lifemed Medical Systems. "It is great that we through Lifemed have won this procu
Change in Aspo’s Group Executive Committee27.6.2022 10:20:00 CEST | Press release
Aspo Plc Stock exchange release June 27, 2022 at 11:20 a.m. Change in Aspo’s Group Executive Committee Heli Arantola, Managing Director of Aspo’s subsidiary Leipurin, has resigned to join another company. Arantola will leave the company in December at the latest, and the process of selecting her successor has begun. “I thank Heli for her excellent contribution to the modernization of Leipurin and transforming the company in the rapidly changing bakery and food industry. I wish her the best of luck in her future endeavors,” says Rolf Jansson, CEO of Aspo Group. Aspo Plc Rolf Jansson CEO Further information, please contact: Rolf Jansson, CEO, Aspo Plc, +358 400 600 264, email@example.com DISTRIBUTION: Nasdaq Helsinki Key media www.aspo.com Aspo creates value by owning and developing business operations sustainably and in the long term. Our companies aim to be market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of
Cool Company Ltd. – Mandatory Notification Of Trade27.6.2022 10:17:48 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 24 June 2022 acquired 7,035 shares in the Company at a price of NOK 89.307527 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,598,523 shares in the Company, equivalent to 38.99% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme27.6.2022 08:45:00 CEST | Press release
Company Announcement No. 43/2022 Copenhagen, 27 June 2022 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. The